Merck & Co. said the Hart-Scott-Rodino waiting period has expired for its pending acquisition of Terns Pharmaceuticals, moving its $53-per-share cash tender offer one step closer to completion. The transaction would give Merck control of TERN-701, Terns Pharmaceuticals’ investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 development for certain patients with chronic myeloid leukemia.

The antitrust clearance is not the finish line, but it materially reduces one source of uncertainty around the deal. For Merck, the more important question is no longer whether regulators see a competition problem in the acquisition. It is whether TERN-701 can mature from a promising clinical-stage asset into a commercially meaningful hematology product at a time when large pharmaceutical companies are paying up for differentiated oncology mechanisms, longer patent lives, and cleaner lifecycle stories.

Why the HSR clearance matters for Merck’s Terns acquisition even though the clinical risk remains unresolved

The expiration of the Hart-Scott-Rodino waiting period removes a procedural barrier from Merck’s acquisition of Terns Pharmaceuticals, but the tender offer still depends on the satisfaction of other conditions, including the tender of more than 50 percent of Terns Pharmaceuticals’ outstanding shares. That matters because the deal is structured not as a conventional slow-moving merger vote story, but as a cash tender offer designed to move quickly if shareholders support the transaction.

From a deal execution standpoint, the clearance is a positive signal. It suggests that U.S. antitrust authorities did not see enough horizontal overlap or market concentration risk to delay the transaction further. That is not surprising. Terns Pharmaceuticals is a clinical-stage company, and TERN-701 is not yet a commercial product competing directly in the market. For Merck, therefore, the regulatory issue was always likely to be less complicated than the clinical and strategic questions surrounding the asset.

The risk now shifts from transaction mechanics to value realization. Merck is not buying marketed revenue. It is buying an investigational hematology candidate and the possibility that TERN-701 can compete in a treatment landscape where efficacy, tolerability, sequencing, and long-term response durability will all matter. That is a very different kind of risk from antitrust review. It is also exactly the kind of risk large pharmaceutical companies are increasingly willing to absorb when the scientific rationale is strong enough and the commercial runway looks long enough.

How TERN-701 fits Merck’s need to diversify beyond its dominant oncology franchise

Merck’s interest in Terns Pharmaceuticals sits squarely inside a larger industry pattern. Large pharmaceutical companies are trying to refresh late-stage and mid-stage pipelines before major revenue concentration becomes a bigger investor concern. In Merck’s case, that concern is especially visible because Keytruda remains one of the most important oncology products in the global pharmaceutical market, and future patent pressure continues to shape how investors evaluate the company’s long-term growth story.

TERN-701 gives Merck a different kind of oncology exposure. Chronic myeloid leukemia is not a massive solid tumor market, but it is a clinically durable category in which patients often remain on therapy for extended periods. That creates a market structure where improved tolerability, deeper molecular responses, and sequencing advantages can matter commercially, even when the patient population is narrower than in lung cancer, melanoma, or breast cancer.

The strategic appeal is also that TERN-701 is an oral targeted therapy rather than a complex biologic or cell therapy. Oral oncology products can be easier to scale globally than highly individualized treatment platforms, although they still require strong clinical differentiation and clear physician confidence. For Merck, the asset could add depth to hematology while also reducing dependence on immuno-oncology alone. That is not a magic fix for the Keytruda cliff, but it is the kind of targeted pipeline addition that can help build a broader post-Keytruda earnings bridge.

Why chronic myeloid leukemia remains commercially attractive despite being a more mature treatment category

Chronic myeloid leukemia has already been transformed by tyrosine kinase inhibitors, which means any new entrant has to clear a higher bar than simply showing activity. Clinicians will want to understand where TERN-701 fits in relation to established active-site inhibitors and newer allosteric approaches. The commercial opportunity will depend on whether it can demonstrate clinically meaningful advantages in patients who have already cycled through prior therapy, cannot tolerate existing drugs, or need a different resistance-management strategy.

That makes the CARDINAL trial central to the Merck thesis. A Phase 1/2 study can provide early evidence of dose, safety, and molecular response, but it cannot by itself settle the commercial positioning of the drug. Investors and physicians will want to see whether responses deepen over time, whether tolerability holds up with longer follow-up, and whether the drug’s mechanism translates into a practical advantage in real-world sequencing. In chronic diseases with long treatment duration, early activity is useful, but durability and safety often decide adoption.

The challenge is that chronic myeloid leukemia is not an empty field. Physicians already have experience managing patients across multiple tyrosine kinase inhibitors. A new asset must justify not only regulatory approval, but also changes in prescribing behaviour. That means Merck will eventually need a compelling evidence package that addresses both clinical efficacy and day-to-day usability. In a mature category, being new is not enough. Being meaningfully better is the admission ticket.

What Merck is really buying in Terns Pharmaceuticals beyond a single clinical-stage asset

Although TERN-701 is the obvious centerpiece, Merck is also buying optionality. Clinical-stage acquisitions are rarely valued solely on one data point. They are valued on the possibility that a platform, molecule, intellectual property position, development team, or disease-area foothold can become more valuable inside a larger company with global development and commercialization infrastructure.

For Terns Pharmaceuticals, the deal provides shareholders with a cash exit at a time when clinical-stage biotech funding remains selective and public-market appetite is uneven. For Merck, it provides control over an asset that might otherwise have become more expensive if later-stage data strengthened the case for best-in-class potential. This is the central tension in biotech M&A: buyers pay before uncertainty disappears because waiting for certainty usually means paying much more, or losing the asset to a rival.

That does not make the transaction risk-free. The valuation places pressure on TERN-701 to deliver a differentiated clinical profile. If the asset merely performs adequately, the strategic rationale becomes less compelling. If it demonstrates superior response, tolerability, or sequencing utility, the deal could look more disciplined in hindsight. The spread between those two outcomes is why oncology dealmaking still rewards scientific judgment as much as financial capacity.

How investors are likely to read the Terns deal after the antitrust milestone

Investor reaction to the HSR clearance is likely to be measured rather than dramatic because the regulatory step was expected to be manageable. The more important investor debate is whether Merck is assembling enough credible pipeline depth to offset future pressure on its largest revenue drivers. In that context, the Terns acquisition is useful, but not sufficient by itself. It adds a potentially important hematology asset, but it does not remove the need for broader portfolio execution across oncology, cardiometabolic disease, vaccines, and other growth areas.

For Terns Pharmaceuticals shareholders, the tender condition now becomes the practical focus. A cash offer can be attractive in a volatile biotech market, especially when the target remains clinical-stage and faces the normal risks of drug development. However, the quality of TERN-701 also creates the possibility that some investors may view the asset as more valuable over a longer horizon. That is the familiar biotech shareholder dilemma: certainty today versus upside tomorrow.

For Merck shareholders, the question is whether management can keep deploying capital into assets that are scientifically differentiated, commercially scalable, and financially disciplined. The Terns transaction fits the first two tests on paper. The third test will only become clear after more data.

What clinicians, regulators, and industry observers will watch next for TERN-701

The next phase of scrutiny will focus less on the acquisition process and more on the evidence behind TERN-701. Clinicians will watch molecular response rates, dose selection, adverse event patterns, discontinuation rates, and signs that the drug can be used comfortably in patients who have already experienced failure, intolerance, or suboptimal response with earlier tyrosine kinase inhibitors. Regulators will look for a development pathway that is rigorous enough to support approval in a defined chronic myeloid leukemia population.

Commercial teams will also have their own questions. Can TERN-701 be positioned clearly against existing options? Will payers accept the value proposition if the drug enters a category with several established therapies? Can Merck use its global oncology infrastructure to accelerate uptake without overpromising the asset before confirmatory data mature? These are not minor details. In oncology, strong science opens the door, but clean positioning keeps the product alive commercially.

The HSR clearance therefore changes the transaction timeline more than it changes the scientific thesis. Merck is now closer to owning Terns Pharmaceuticals, but the deeper story remains clinical execution. TERN-701 may strengthen Merck’s hematology ambitions and support a more diversified oncology future. However, the asset still has to prove that its allosteric mechanism, oral profile, and early-stage promise can translate into durable benefit for chronic myeloid leukemia patients and durable value for Merck.

  BCR::ABL1, CARDINAL trial, chronic myeloid leukemia, hematology, Merck & Co., oncology, TERN-701, Terns Pharmaceuticals